bioRxiv Science⌕ Search

Biology subjects

Shameem, M.

Publications and source records attributed to Shameem, M..

5 recordsLinked to original sources

Macrophages use sub-micron actin ridges in phagocytosis of encapsulated fungal pathogens

Ingestion and killing of pathogens by phagocytic cells is a key aspect of animal immunity. Cryptococcus neoformans is a major pathogen of AIDS patients that has a polysaccharide capsule that is critical for virulence. Phagocytic function is necessary for normal immunity to cryptococcal infection, and we sought to determine how Cryptococcus capsule prevents phagocytosis. In doing so, we discovered a new sub-micron actin structure, the ridge, that is present on macrophages, neutrophils and amoebae. Macrophages preferentially bind cryptococci via ridges and suppression of ridges is sufficient to prevent phagocytosis. Ridges are present on macrophages in vivo and are lost in interleukin 10 stimulated macrophages. The discovery and functional description of macrophage surface ridges fills a critical gap in our understanding of how phagocytes ingest encapsulated fungal pathogens, a crucial step in treating infection.

cell biology↗

Cryoaerosolization Enables Scalable Vitrification-Based Cell Cryopreservation

Cell therapies hold transformative potential for treating cancer, neurologic disorders, organ failure, diabetes, and other conditions, but their widespread clinical deployment is constrained by the lack of scalable cryopreservation methods that maintain high post-thaw viability. Current standard practice using slow freezing can lead to cell death and impaired cell function. Vitrification offers an alternative by cooling samples rapidly enough to bypass ice formation entirely, better preserving cell structure and function. The high cooling and warming rates required for vitrification have previously been achieved by quenching microliter-scale samples directly into convective cooling and warming baths. Here, we present a cryopreservation platform that overcomes the throughput limitations of existing systems by combining a vibrating orifice aerosol generator with an impinging conical nozzle to generate and confine micrometer-scale droplets mid-flight in liquid nitrogen. This approach mitigates cooling losses due to the inverse Leidenfrost effect, increasing cooling and warming rates by nearly an order of magnitude compared to conventional droplet vitrification, while improving throughput by two orders of magnitude. To test the efficacy of this system, we cryoaerosolized and rewarmed human induced pluripotent stem cells, porcine red blood cells, and human dermal fibroblasts using only 190-25 wt% (2.5-3.7 M) permeating cryoprotective agent, achieving >90% post-thaw viability for HDFs and hiPSCs and 94% recovery for RBCs, with retained colony-forming capacity additionally demonstrated in hiPSCs. This work demonstrates the first scalable vitrification-based cryopreservation method capable of achieving both high cooling ({approx} 200, 000 K min-1) and warming rates ({approx} 1, 000, 000 K min-1) while maintaining the high-throughput processing required ([≥]100 mL h-1) for next-generation cell therapies. Significance StatementCell therapies require robust long-term storage methods to enable widespread clinical deployment. Current approaches utilizing refrigeration or small-scale vitrification cannot meet the scalability and viability requirements for next-generation therapeutics. In this work we demonstrate a cryoaerosolization process that achieves both ultra-rapid cooling rates (>200,000 {degrees}C min-1) and high throughput (>100 mL h-1) by generating micrometer-scale droplets and spraying in a liquid nitrogen impingement stream. Using only as little as 19 wt% cryoprotectant, we achieved >90% cell viability and maintained function, comparable to low-throughput methods, but at two orders of magnitude higher processing rates. We also introduce a just-in-time CPA loading approach that reduces toxicity exposure. This technique enables scalable vitrification-based cryopreservation of large-volume cell products.

bioengineering↗

Developmental regulation of progenitor aging shapes long-term intestinal homeostasis in Drosophila

Aging causes a progressive loss of tissue homeostasis, with stem cell exhaustion as a major hallmark. Age-associated decline in organ function is widely perceived as emanating from progressive accumulation of cellular damage in adult tissues. However, whether aging trajectories are established early on during development remains an open question. Here, we demonstrate that genetic modulation of cellular aging pathways in larval adult midgut progenitors (AMPs), which serve as the precursors of adult intestinal stem cells and differentiated epithelial cells, dictates the long-term trajectory of intestinal aging in Drosophila. Accelerated cellular aging by genetic perturbation employing Toll or Imd pathway overactivation or elevation of reactive oxygen species (ROS) using ND42 (mitochondrial complex I) knockdown in the AMPs results in aberrant progenitor proliferation, skewed lineage allocation, epithelial barrier dysfunction, and genomic instability. These alterations are accompanied by marked destabilization of AMP islet architecture and widespread changes in age-related molecular signatures, as revealed by bulk transcriptomic analysis. In contrast, decelerated cellular aging mediated by Foxo or Atg8a overexpression results in a decrease in enteroendocrine population and the intestinal barrier remained unaffected. Intriguingly, early-life activation of immune and oxidative stress signaling manifested later in the adult gut as elevated enteroendocrine differentiation, highlighting lasting effects on intestinal regenerative capacity and lineage balance. Together, our findings demonstrate that cellular aging is tightly regulated early on in development and its perturbation can cause developmental disruption hampering adult gut homeostasis, establishing AMPs as key developmental determinants that regulate the trajectory of intestinal aging in Drosophila.

developmental biology↗

PROPERMAB: an integrative framework for in silico prediction of antibody developability using machine learning

Selection of lead therapeutic molecules is often driven predominantly by pharmacological efficacy and safety. Candidate developability, such as biophysical properties that affect the formulation of the molecule into a product, is usually evaluated only toward the end of the drug development pipeline. The ability to evaluate developability properties early in the process of antibody therapeutic development could accelerate the timeline from discovery to clinic and save considerable resources. In silico predictive approaches, such as machine learning models, which map molecules to predictions of developability properties could offer a cost-effective and high-throughput alternative to experiments for antibody developability assessment. We developed a computational framework, PROPERMAB, for large-scale and efficient in silico prediction of developability properties for monoclonal antibodies, using custom molecular features and machine learning modeling. We demonstrate the power of PROPERMAB by using it to develop models to predict antibody hydrophobic interaction chromatography retention time and high-concentration viscosity. We further show that structure-derived features can be rapidly and accurately predicted directly from sequences by pre-training simple models for molecular features, thus providing the ability to scale these approaches to repertoire-scale sequence datasets.

bioinformatics↗

HCM-associated mutations in MYH6/7 drive pathologic expression of TGF-β1 in cardiomyocytes within weeks of developmental specification

Hypertrophic cardiomyopathy (HCM) is characterized by myocyte hypertrophy, sarcomere disarray, and myocardial fibrosis, leading to significant morbidity and mortality. As the most common inherited cardiomyopathy, HCM largely results from mutations in sarcomeric protein genes. Current treatments for HCM primarily focus on alleviating late-stage symptoms, with a critical gap in the detailed understanding of early-stage deficiencies that drive disease progression. We recently showed, in monolayers of cardiomyocytes derived from human induced pluripotent stem cells (hiPSCs) with MYH7 R723C and MYH6 R725C mutations, altered expression of several extracellular matrix (ECM)-related genes with associated defects in cardiomyocyte-ECM adhesion. To better evaluate the cardiomyocyte-ECM interface and pathological ECM dynamics in early-stage HCM, here we adopted a 3D engineered heart tissue (EHT) model containing both cardiomyocytes and fibroblasts, the primary contributor to ECM remodeling. Mutant EHTs showed aberrant cardiomyocyte distribution, augmented calcium handling, and force generation compared to controls. Altered proteoglycan deposition and increased phosphorylated focal adhesion kinase (pFAK) further indicated changes in ECM composition and connectivity. Elevated transforming growth factor beta-1 (TGF-{beta}1) secretion and a higher proportion of activated fibroblasts were identified in mutant EHTs, along with sustained TGF-{beta}1 transcription specifically in mutant cardiomyocytes. Remarkably, blocking TGF-{beta}1 receptor signaling reduced fibroblast activation and contraction force to control levels. This study underscores the early interplay of mutant hiPSC-CMs with fibroblasts, wherein mutant cardiomyocytes initiate fibroblast activation via TGF-{beta}1 overexpression, independent of the immune system. These findings provide a promising foundation for developing and implementing novel strategies to treat HCM well before the manifestation of clinically detectable fibrosis and cardiac dysfunction.

bioengineering↗